Content area

Abstract

Background

Patients with ulcerative colitis (UC) are at increased risk for infections such as Clostridium difficile and cytomegalovirus (CMV) colitis due to chronic immunosuppression. These patients often undergo multiple surgeries putting them at risk for recurrence of the infection. However, rates of recurrence in this setting and outcomes are not well understood.

Aim

The aim of this study is to determine rates of recurrence of C difficile and CMV infection in patients undergoing multistage UC surgeries and effects of antibiotic prophylaxis on outcomes.

Methods

All patients with UC who underwent IPAA between 2001 and 2017 (at two tertiary referral centers were identified. History of C. difficile or CMV colitis prior to any surgery and recurrence after IPAA was noted

Results

A total of 633 patients with UC who underwent IPAA were identified, of whom 8.1% patients had C. difficile and 2.7% had CMV infections. 9.8% of C. difficile and 5.9% of CMV patients recurred after IPAA. Rates of abdominal sepsis (14.7% vs. 12.7%), 90-day mortality (0% vs. 0.4%), pouchitis (36.8% vs. 45.0%), or return to stoma (7.4% vs. 5.4%) were similar between patients who did or did not have infections. In patients with C. difficile infection prior to first surgery, none of the patients who received prophylaxis had recurrent infection.

Conclusions

Rates of C. difficile and CMV infections remain high in patients undergoing surgery for UC, with substantial minority developing recurrent infection during subsequent surgical procedures. Antibiotic prophylaxis in patients with a history of C difficile may reduce the rate of recurrent infection.

Details

Title
Recurrence of Clostridium Difficile and Cytomegalovirus Infections in Patients with Ulcerative Colitis Who Undergo Ileal Pouch-Anal Anastomosis
Author
Del Valle Jonathan Pastrana 1 ; Lee, Grace C 2 ; Serrato Jose Cataneo 3 ; Feuerstein, Joseph D 4 ; Bordeianou, Liliana Grigorievna 2 ; Hodin, Richard 2 ; Kunitake Hiroko 5 ; Poylin Vitaliy 6 

 Beth Israel Deaconess Medical Center, Department of Surgery, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Massachusetts General Hospital, Division of Gastrointestinal and Oncologic Surgery, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Beth Israel Deaconess Medical Center, Department of Surgery, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Massachusetts General Hospital, Division of Gastrointestinal and Oncologic Surgery, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Beth Israel Deaconess Medical Center Medicine, Division of Gastroenterology, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Advocate Illinois Masonic Medical Center, Chicago, USA (GRID:grid.413330.6) (ISNI:0000 0004 0435 6194) 
 Northwestern Medicine, Arkes Family Pavilion, Division of Gastrointestinal and Oncologic Surgery, Chicago, USA (GRID:grid.490348.2) (ISNI:0000000446839645) 
Pages
4441-4447
Publication year
2021
Publication date
Dec 2021
Publisher
Springer Nature B.V.
ISSN
01632116
e-ISSN
15732568
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2596811264
Copyright
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021.